Kura Net Income from 2010 to 2026
| KURA Stock | USD 7.85 0.01 0.13% |
Net Loss | First Reported 2008-12-31 | Previous Quarter -66.1 M | Current Value -74.1 M | Quarterly Volatility 18.8 M |
Check Kura Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kura Oncology's main balance sheet or income statement drivers, such as Other Operating Expenses of 298.3 M, Total Operating Expenses of 298.3 M or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 11.14, Dividend Yield of 0.0 or PTB Ratio of 1.98. Kura financial statements analysis is a perfect complement when working with Kura Oncology Valuation or Volatility modules.
Kura | Net Income | Build AI portfolio with Kura Stock |
Analyzing Kura Oncology's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Kura Oncology's current valuation and future prospects.
Latest Kura Oncology's Net Income Growth Pattern
Below is the plot of the Net Income of Kura Oncology over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Kura Oncology financial statement analysis. It represents the amount of money remaining after all of Kura Oncology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Kura Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kura Oncology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (173.98 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Kura Net Income Regression Statistics
| Arithmetic Mean | (71,071,443) | |
| Coefficient Of Variation | (91.82) | |
| Mean Deviation | 57,692,360 | |
| Median | (60,447,000) | |
| Standard Deviation | 65,258,638 | |
| Sample Variance | 4258.7T | |
| Range | 174M | |
| R-Value | (0.96) | |
| Mean Square Error | 347.2T | |
| R-Squared | 0.92 | |
| Slope | (12,419,441) | |
| Total Sum of Squares | 68139T |
Kura Net Income History
Other Fundumenentals of Kura Oncology
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Kura Oncology Net Income component correlations
About Kura Oncology Financial Statements
Kura Oncology stakeholders use historical fundamental indicators, such as Kura Oncology's Net Income, to determine how well the company is positioned to perform in the future. Although Kura Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kura Oncology's assets and liabilities are reflected in the revenues and expenses on Kura Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kura Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -156.6 M | -148.8 M | |
| Net Loss | -156.6 M | -148.8 M | |
| Net Loss | -122.3 M | -116.1 M | |
| Net Loss | (2.32) | (2.44) | |
| Net Income Per E B T | 0.91 | 0.81 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out the analysis of Kura Oncology Correlation against competitors. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. Expected growth trajectory for Kura significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kura Oncology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Kura Oncology requires distinguishing between market price and book value, where the latter reflects Kura's accounting equity. The concept of intrinsic value - what Kura Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kura Oncology's price substantially above or below its fundamental value.
Understanding that Kura Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kura Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kura Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.